CBLIF and hepatocellular carcinoma: In addition, these mutations had been related to: increased HCC risk, [12,13], non-virological response to interferon-based therapy in Japanese patients [10], variable responses to double (IFN/RBV) [14,15], and triple therapy (telaprevir plus INF/RBV) [16,17], and liver steatosis [18].